Listen to this article on the DDW Podcast: Dr. Zack Gurard-Levin, Chief Scientific Officer, SAMDI Tech, breaks down three critical components to consider to ensure a successful affinity selection mass spectrometry (ASMS) drug discovery programme. The ability to rapidly identify small molecules that non-covalently bind to a specific target is a critical tool that will benefit many […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!